

Domain:	Reproductive Health
Measure:	Human Papillomavirus Vaccine Use
Definition:	Questions to assess women's use of the human papillomavirus vaccine.
Purpose:	These questions ascertain if a woman received the human papillomavirus vaccine and if so, the number of doses received. Use of the vaccine impacts a woman's risk of developing cervical cancer and the overall incidence rate of cervical cancer.
Essential PhenX Measures:	Current Age Gender
Related PhenX Measures:	None
Keywords:	Reproductive health, human papillomavirus, vaccination, infectious disease prevention, genital wart prevention, Behavioral Risk Factor Surveillance System (BRFSS), GARDASIL®, Silgard, CERVARIX®
Measure Release Date:	TBD

Protocol Release Date:	TBD
PhenX Protocol Name:	Human Papillomavirus Vaccine Use
Protocol Name from Source:	The Expert Review Panel has not reviewed this measure yet.
Description:	The interviewer asks the female participant whether she has ever received a human papillomavirus (HPV) vaccination. If she answers yes, the interviewer asks her age and how many shots she received.
Specific Instructions:	<p>If the participant answers "yes" to question 1, the interviewer should complete the rest of the protocol. If the participant answers "no" then the protocol is deemed complete.</p> <p>The PhenX Working Group notes that GARDASIL® is also known as Silgard, internationally.</p> <ul style="list-style-type: none"> • European Medicines Agency. (September 25, 2009). Silgard European Public Assessment Report. Retrieved from http://www.emea.europa.eu/humandocs/Humans/EPAR/silgard/silgard.htm. • Waknine, Yael. (October 2, 2006). International Approvals: Singulair and Gardasil/Silgard. Medscape Today. Retrieved from http://www.medscape.com/viewarticle/545374.

	<p>Note: GARDASIL® by Merck & Co. is approved by the FDA for use in females ages 9-26 and males ages 9-26.</p> <p>Note: CERVARIX® is manufactured by GlaxoSmithKline Biologicals and approved by the FDA for use in females ages 10-25.</p>
Protocol:	<p>1. A vaccine to prevent the human papillomavirus or HPV infection is available and is called the cervical cancer or genital warts vaccine, HPV shot, [Fill: if female “GARDASIL or CERVARIX”; if male “ or GARDASIL”]. Have you EVER had an HPV vaccination?</p> <p><input type="checkbox"/> 1 Yes</p> <p><input type="checkbox"/> 2 No (skip to end)</p> <p><input type="checkbox"/> 3 Doctor refused when asked (skip to end)</p> <p><input type="checkbox"/> 7 Don't know / Not sure (skip to end)</p> <p><input type="checkbox"/> 9 Refused (skip to end)</p> <p>2. How many HPV shots did you receive?</p> <p><input type="checkbox"/> __ Number of shots;</p> <p><input type="checkbox"/> 03 All shots;</p> <p><input type="checkbox"/> 77 Don't know/ Not sure;</p> <p><input type="checkbox"/> 99 Refused</p> <p>GARDASIL® is a registered trademark of Merck & Co., Inc.</p> <p>CERVARIX® is a registered trademark of GlaxoSmithKline, Inc.</p>
Selection Rationale:	<p>The Behavioral Risk Factor Surveillance System is telephone interview surveillance system sponsored by the Centers for Disease Control and Prevention gathering data in all 50 states and the District of Columbia. It introduced questions human papillomavirus (HPV) vaccine in 2009. As HPV vaccine has only recently been approved by the Food and Drug Administration (June 2006), earlier national surveys did not include the HPV vaccine in their protocols.</p>
Source:	<p>Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System (BRFSS) 2014. Module 11 questions 1 & 2.</p>
Life Stage:	<p>Adult</p>
Language:	<p>English</p>

Participant:	Females ages 18-49.										
Personnel and Training Required:	The interviewer must be trained to conduct personal interviews with individuals from the general population. The interviewer must be trained and found to be competent (i.e., tested by an expert) at the completion of personal interviews.										
Equipment Needs:	Paper and pencil										
General References:	Hariri, S., Markowitz, L.E., Bennett, N.M., Niccolai, L.M., Schafer, S., Bloch, K., et al. (2015). Monitoring effect of human papillomavirus vaccines in US population, Emerging Infections Program, 2008–2012. <i>Emerg Infect Dis.</i> . Williams WW, Lu P, O’Halloran A, et al. (2016). Surveillance of Vaccination Coverage Among Adult Populations — United States, 2014. <i>MMWR Surveill Summ</i> , 65(No. SS-1):1–36.										
Mode of Administration:	Interviewer-administered questionnaire										
Derived Variables:	None										
Requirements:	<table border="1"> <thead> <tr> <th>Requirement Category</th> <th>Required</th> </tr> </thead> <tbody> <tr> <td>Major equipment</td> <td>No</td> </tr> <tr> <td>Specialized training</td> <td>No</td> </tr> <tr> <td>Specialized requirements for biospecimen collection</td> <td>No</td> </tr> <tr> <td>Average time of greater than 15 minutes in an unaffected individual</td> <td>No</td> </tr> </tbody> </table>	Requirement Category	Required	Major equipment	No	Specialized training	No	Specialized requirements for biospecimen collection	No	Average time of greater than 15 minutes in an unaffected individual	No
Requirement Category	Required										
Major equipment	No										
Specialized training	No										
Specialized requirements for biospecimen collection	No										
Average time of greater than 15 minutes in an unaffected individual	No										
Annotations for Specific Conditions:	None at this time.										
Process and Review:	<p>The Expert Review Panel #5 (ERP 5) reviewed the measures in the Reproductive Health domain.</p> <p>Guidance from ERP 5 includes:</p> <ul style="list-style-type: none"> • Updated the protocol (same source) <p>Back-compatible: Partially back-compatible (updated/similar protocol which would require some changes to the data dictionary), variable mapping between current and previous protocols can be found here <link></p> <p>Previous version in Toolkit archive (link)</p>										